Malignant Mesothelioma-Pipeline Review, H1 2015

Malignant Mesothelioma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6582IDB
  • |
  • Pages: 303
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Malignant Mesothelioma-Pipeline Review, H1 2015


Global Markets Direct's, 'Malignant Mesothelioma-Pipeline Review, H1 2015', provides an overview of the Malignant Mesothelioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Malignant Mesothelioma Overview 9

Therapeutics Development 10

Pipeline Products for Malignant Mesothelioma-Overview 10

Pipeline Products for Malignant Mesothelioma-Comparative Analysis 11

Malignant Mesothelioma-Therapeutics under Development by Companies 12

Malignant Mesothelioma-Therapeutics under Investigation by Universities/Institutes 17

Malignant Mesothelioma-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Malignant Mesothelioma-Products under Development by Companies 23

Malignant Mesothelioma-Products under Investigation by Universities/Institutes 27

Malignant Mesothelioma-Companies Involved in Therapeutics Development 28

Aduro BioTech, Inc. 28

Advantagene, Inc. 29

Aeolus Pharmaceuticals, Inc. 30

Amphera BV 31

Applied Research using OMIC Sciences, S.L. 32

arGEN-X BV 33

ArQule, Inc. 34

AVEO Pharmaceuticals, Inc. 35

Bayer AG 36

Biogen, Inc. 37

Bionomics Limited 38

Biotecnol, Inc. 39

Boehringer Ingelheim GmbH 40

Boston Biomedical, Inc. 41

Bristol-Myers Squibb Company 42

Calithera Biosciences, Inc. 43

CanBas Co., Ltd. 44

Concordia Healthcare Corp. 45

CritiTech, Inc. 46

Deciphera Pharmaceuticals, LLC 47

Eagle Pharmaceuticals, Inc. 48

Eisai Co., Ltd. 49

Eli Lilly and Company 50

EnGeneIC Ltd 51

F. Hoffmann-La Roche Ltd. 52

Five Prime Therapeutics, Inc. 53

Formula Pharmaceuticals, Inc. 54

Genelux Corporation 55

GlaxoSmithKline plc 56

Juno Therapeutics Inc. 57

Kyowa Hakko Kirin Co., Ltd. 58

MedImmune, LLC 59

Merck & Co., Inc. 60

Merck KGaA 61

Millennium Pharmaceuticals, Inc. 62

MolMed S.p.A. 63

Morphotek, Inc. 64

Novartis AG 65

Oncos Therapeutics Ltd. 66

Oxford BioMedica plc 67

Pfizer Inc. 68

Pharma Mar, S.A. 69

Polaris Pharmaceuticals, Inc. 70

Sellas Inc. 71

SentoClone International AB 72

Synta Pharmaceuticals Corp. 73

VasGene Therapeutics, Inc. 74

Verastem, Inc. 75

Virttu Biologics Limited 76

Y's Therapeutics Co., Ltd. 77

Malignant Mesothelioma-Therapeutics Assessment 78

Assessment by Monotherapy Products 78

Assessment by Combination Products 79

Assessment by Target 80

Assessment by Mechanism of Action 83

Assessment by Route of Administration 86

Assessment by Molecule Type 88

Drug Profiles 90

AEOL-10150-Drug Profile 90

alisertib-Drug Profile 93

amatuximab-Drug Profile 97

anetumab ravtansine-Drug Profile 100

ARGX-110-Drug Profile 102

ascrinvacumab-Drug Profile 105

AV-203-Drug Profile 106

avelumab-Drug Profile 107

BERTA-Drug Profile 109

BG-00001-Drug Profile 110

BIW-8962-Drug Profile 111

BMS-986148-Drug Profile 112

BNC-105-Drug Profile 113

CB-839-Drug Profile 114

CBP-501-Drug Profile 116

Cell Therapy 1 for Oncology-Drug Profile 118

CRS-207-Drug Profile 119

defactinib hydrochloride-Drug Profile 122

Dendritic Cell Therapy for Cancer-Drug Profile 124

Dendritic Cell Therapy for Oncology and Infectious Disease-Drug Profile 125

DP-3975-Drug Profile 126

DPV-001-Drug Profile 127

E-7449-Drug Profile 129

FP-1039-Drug Profile 130

FPI-01-Drug Profile 132

ganetespib-Drug Profile 134

Gene Therapy for Malignant Pleural Mesothelioma-Drug Profile 138

Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma-Drug Profile 139

GLONC-1-Drug Profile 140

GSK-2256098-Drug Profile 143

HSV-1716-Drug Profile 144

iCasp9M28z-Drug Profile 146

JTCR-016-Drug Profile 147

LY-3023414-Drug Profile 148

MesoCancerVac-Drug Profile 150

MesoCART-Drug Profile 151

Monoclonal Antibody Conjugated to Target Mesothelin for Oncology-Drug Profile 152

MV-NIS-Drug Profile 154

napabucasin-Drug Profile 156

NGR-hTNF-Drug Profile 159

nintedanib-Drug Profile 163

ONCOS-102-Drug Profile 168

Oshadi D + Oshadi R-Drug Profile 169

paclitaxel-Drug Profile 170

pegargiminase-Drug Profile 171

pembrolizumab-Drug Profile 174

pemetrexed disodium-Drug Profile 181

porfimer sodium-Drug Profile 183

Recombinant Protein to Antagonize EphB4 Receptor for Oncology-Drug Profile 184

RG-7787-Drug Profile 186

Sentoclone-Drug Profile 187

Small Molecules to Inhibit Bcl-2 Survival Proteins for Cancer-Drug Profile 189

Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer-Drug Profile 190

TargomiRs-Drug Profile 191

Tb-535-Drug Profile 193

tivantinib-Drug Profile 194

trabectedin-Drug Profile 197

tremelimumab-Drug Profile 201

TroVax-Drug Profile 203

Vaccine for Cancer-Drug Profile 206

Vaccine For Oncolytic Newcastle Disease Virus-Drug Profile 207

Vaccine to Target WT1 for Cancer-Drug Profile 208

VS-5584-Drug Profile 209

YS-110-Drug Profile 211

Malignant Mesothelioma-Recent Pipeline Updates 212

Malignant Mesothelioma-Dormant Projects 284

Malignant Mesothelioma-Discontinued Products 286

Malignant Mesothelioma-Product Development Milestones 287

Featured News & Press Releases 287

Appendix 297

Methodology 297

Coverage 297

Secondary Research 297

Primary Research 297

Expert Panel Validation 297

Contact Us 297

Disclaimer 298

List of Tables

Number of Products under Development for Malignant Mesothelioma, H1 2015 15

Number of Products under Development for Malignant Mesothelioma-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Comparative Analysis by Unknown Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Malignant Mesothelioma-Pipeline by Aduro BioTech, Inc., H1 2015 33

Malignant Mesothelioma-Pipeline by Advantagene, Inc., H1 2015 34

Malignant Mesothelioma-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 35

Malignant Mesothelioma-Pipeline by Amphera BV, H1 2015 36

Malignant Mesothelioma-Pipeline by Applied Research using OMIC Sciences, S.L., H1 2015 37

Malignant Mesothelioma-Pipeline by arGEN-X BV, H1 2015 38

Malignant Mesothelioma-Pipeline by ArQule, Inc., H1 2015 39

Malignant Mesothelioma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 40

Malignant Mesothelioma-Pipeline by Bayer AG, H1 2015 41

Malignant Mesothelioma-Pipeline by Biogen, Inc., H1 2015 42

Malignant Mesothelioma-Pipeline by Bionomics Limited, H1 2015 43

Malignant Mesothelioma-Pipeline by Biotecnol, Inc., H1 2015 44

Malignant Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 45

Malignant Mesothelioma-Pipeline by Boston Biomedical, Inc., H1 2015 46

Malignant Mesothelioma-Pipeline by Bristol-Myers Squibb Company, H1 2015 47

Malignant Mesothelioma-Pipeline by Calithera Biosciences, Inc., H1 2015 48

Malignant Mesothelioma-Pipeline by CanBas Co., Ltd., H1 2015 49

Malignant Mesothelioma-Pipeline by Concordia Healthcare Corp., H1 2015 50

Malignant Mesothelioma-Pipeline by CritiTech, Inc., H1 2015 51

Malignant Mesothelioma-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 52

Malignant Mesothelioma-Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 53

Malignant Mesothelioma-Pipeline by Eisai Co., Ltd., H1 2015 54

Malignant Mesothelioma-Pipeline by Eli Lilly and Company, H1 2015 55

Malignant Mesothelioma-Pipeline by EnGeneIC Ltd, H1 2015 56

Malignant Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 57

Malignant Mesothelioma-Pipeline by Five Prime Therapeutics, Inc., H1 2015 58

Malignant Mesothelioma-Pipeline by Formula Pharmaceuticals, Inc., H1 2015 59

Malignant Mesothelioma-Pipeline by Genelux Corporation, H1 2015 60

Malignant Mesothelioma-Pipeline by GlaxoSmithKline plc, H1 2015 61

Malignant Mesothelioma-Pipeline by Juno Therapeutics Inc., H1 2015 62

Malignant Mesothelioma-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 63

Malignant Mesothelioma-Pipeline by MedImmune, LLC, H1 2015 64

Malignant Mesothelioma-Pipeline by Merck & Co., Inc., H1 2015 65

Malignant Mesothelioma-Pipeline by Merck KGaA, H1 2015 66

Malignant Mesothelioma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 67

Malignant Mesothelioma-Pipeline by MolMed S.p.A., H1 2015 68

Malignant Mesothelioma-Pipeline by Morphotek, Inc., H1 2015 69

Malignant Mesothelioma-Pipeline by Novartis AG, H1 2015 70

Malignant Mesothelioma-Pipeline by Oncos Therapeutics Ltd., H1 2015 71

Malignant Mesothelioma-Pipeline by Oxford BioMedica plc, H1 2015 72

Malignant Mesothelioma-Pipeline by Pfizer Inc., H1 2015 73

Malignant Mesothelioma-Pipeline by Pharma Mar, S.A., H1 2015 74

Malignant Mesothelioma-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 75

Malignant Mesothelioma-Pipeline by Sellas Inc., H1 2015 76

Malignant Mesothelioma-Pipeline by SentoClone International AB, H1 2015 77

Malignant Mesothelioma-Pipeline by Synta Pharmaceuticals Corp., H1 2015 78

Malignant Mesothelioma-Pipeline by VasGene Therapeutics, Inc., H1 2015 79

Malignant Mesothelioma-Pipeline by Verastem, Inc., H1 2015 80

Malignant Mesothelioma-Pipeline by Virttu Biologics Limited, H1 2015 81

Malignant Mesothelioma-Pipeline by Y's Therapeutics Co., Ltd., H1 2015 82

Assessment by Monotherapy Products, H1 2015 83

Assessment by Combination Products, H1 2015 84

Number of Products by Stage and Target, H1 2015 86

Number of Products by Stage and Mechanism of Action, H1 2015 89

Number of Products by Stage and Route of Administration, H1 2015 92

Number of Products by Stage and Molecule Type, H1 2015 94

Malignant Mesothelioma Therapeutics-Recent Pipeline Updates, H1 2015 217

Malignant Mesothelioma-Dormant Projects, H1 2015 289

Malignant Mesothelioma-Dormant Projects (Contd..1), H1 2015 290

Malignant Mesothelioma-Discontinued Products, H1 2015 291

List of Figures

Number of Products under Development for Malignant Mesothelioma, H1 2015 15

Number of Products under Development for Malignant Mesothelioma-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Products, H1 2015 26

Assessment by Monotherapy Products, H1 2015 83

Number of Products by Top 10 Targets, H1 2015 85

Number of Products by Stage and Top 10 Targets, H1 2015 85

Number of Products by Top 10 Mechanism of Actions, H1 2015 88

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 88

Number of Products by Top 10 Routes of Administration, H1 2015 91

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 92

Number of Products by Top 10 Molecule Types, H1 2015 93

Number of Products by Stage and Top 10 Molecule Types, H1 2015 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Aduro BioTech, Inc.

Advantagene, Inc.

Aeolus Pharmaceuticals, Inc.

Amphera BV

Applied Research using OMIC Sciences, S.L.


ArQule, Inc.

AVEO Pharmaceuticals, Inc.

Bayer AG

Biogen, Inc.

Bionomics Limited

Biotecnol, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

CanBas Co., Ltd.

Concordia Healthcare Corp.

CritiTech, Inc.

Deciphera Pharmaceuticals, LLC

Eagle Pharmaceuticals, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EnGeneIC Ltd

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Formula Pharmaceuticals, Inc.

Genelux Corporation

GlaxoSmithKline plc

Juno Therapeutics Inc.

Kyowa Hakko Kirin Co., Ltd.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Morphotek, Inc.

Novartis AG

Oncos Therapeutics Ltd.

Oxford BioMedica plc

Pfizer Inc.

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

Sellas Inc.

SentoClone International AB

Synta Pharmaceuticals Corp.

VasGene Therapeutics, Inc.

Verastem, Inc.

Virttu Biologics Limited

Y's Therapeutics Co., Ltd.

Malignant Mesothelioma Therapeutic Products under Development, Key Players in Malignant Mesothelioma Therapeutics, Malignant Mesothelioma Pipeline Overview, Malignant Mesothelioma Pipeline, Malignant Mesothelioma Pipeline Assessment

select a license

Single User License
USD 2000 INR 129780
Site License
USD 4000 INR 259560
Corporate User License
USD 6000 INR 389340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]